Latest News

Early results from MesomiR 1 trial published

The first results from the MesomiR 1 trial, a phase I clinical trial of a targeted delivery of a microRNA-based therapy, were published yesterday in the American Journal of Respiratory and Critical Care Medicine The trial is a collaboration between ADRI, the Sydney-based biotech company EnGeneIC Ltd and three hospitals…

Read More

Prof Nico van Zandwijk wins inaugural Dr J Stumphius Recognition Award

The Dr. J. Stumphius Recognition Award, sponsored by Shield Group International, was awarded to Prof. Nico van Zandwijk (ADRI) for his groundbreaking discovery in treating the asbestos cancer called mesothelioma, providing hope and saving lives of untold many people. The award, showing a glass plate on a bronze base, signifying…

Read More

ADRI Scientist awarded PhD scholarship

Marissa Williams, a Research Assistant at ADRI, was recently awarded a full PhD scholarship from Sydney Catalyst to support her PhD studies at The University of Sydney. This highly competitive and sought after award will allow Marissa to embark on PhD studies, putting to use the experience she has gained…

Read More

ADRI publishes new research

The team at ADRI recently had their work on the use of a tumour microRNA signature to predict outcomes in malignant pleural mesothelioma patients accepted for publication in the journal Molecular Oncology. See the article here

Read More

ADRI Scientists present at the 2014 iMig Conference

Researchers from ADRI were well represented at the recent International Mesothelioma Interest Group (iMig) Conference, which was held from 21-24 October in Cape Town. A large number of presentations were made, including 7 short talks and 5 posters, reflecting the broad spectrum of research carried out at ADRI. Find details…

Read More

ADRI Publishes new research

A study led by ADRI Researcher Dr Anthony Linton has recently appeared in the British Journal of Cancer. The article explores the clinical, pathological and treatment factors associated with prolonged survival in malignant pleural mesothelioma. In a large series of 910 patients registered with the NSW Dust Diseases Board, the…

Read More

Open Day for Honours and Phd Students

ADRI, together with its neighbour the ANZAC Research Institute, is actively seeking high calibre honours and PhD candidates who demonstrate initiative and innovative thought for Hounours and PhD projects focusing on cancer research.   Why choose Cancer Research at Concord Clinical School?   We host state of the art research…

Read More

MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC

MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC The ADRI, together with biotech company EnGeneIC, is running an early stage clinical trial of a new approach to therapy for selected patients with malignant pleural mesothelioma or non-small…

Read More

ADRI-led team wins award for rapid progress to clinical trial

The Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented on Friday, August 22, to those leading the way in their field. Dr Glen Reid, from the Asbestos Disease Research Institute, accepted one of the…

Read More

Mesothelioma Support Coordinator

Jocelyn McLean joins the Asbestos Diseases Research Institute (ADRI), after many years of caring for patients having surgery for lung cancer, mesothelioma and benign conditions at Royal Prince Alfred Hospital. Utilising her knowledge and experience of patient and carer needs and drawing from current survivorship research and carer need research…

Read More